Functionalizing nanoparticles with ligands targeting transferrin receptors (TfR), insulin receptors (IR), or low-density lipoprotein receptors (LDLR) has demonstrated increased BBB penetration in preclinical GBM models [6]. The gene discussed is LDLR; the disease is glioblastoma.